The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
ASKA, Kyorin to Jointly Develop Benign Prostatic Hyperplasia Drug
Kyorin Pharmaceutical will jointly develop and commercialize ASKA Pharmaceutical’s investigational benign prostatic hyperplasia treatment AKP-009, the two companies said on September 30. Discovered by ASKA, AKP-009 is a novel androgen receptor modulator expected to shrink the prostate while improving urinary…
To read the full story
Related Article
- ASKA, Kyorin End Partnership on BPH Drug AKP-009
August 5, 2025
BUSINESS
- Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
January 13, 2026
- Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
January 13, 2026
- Daito Secures China Approval for EquMet Generic
January 13, 2026
- Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
January 13, 2026
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…